ASX - By Stock
|
PAR |
Re:
2b or NOT to be
|
|
5cata
|
84 |
30K |
1 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
84
|
30K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Launches $66M Capital Raising
|
|
5cata
|
132 |
56K |
5 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
132
|
56K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
5cata
|
276 |
107K |
3 |
12/08/22 |
12/08/22 |
ASX - By Stock
|
276
|
107K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
5cata
|
276 |
107K |
0 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
276
|
107K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
5cata
|
276 |
107K |
6 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
276
|
107K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
5cata
|
36 |
14K |
4 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
36
|
14K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
WTF- what's with the share price movement
|
|
5cata
|
129 |
59K |
15 |
09/08/22 |
09/08/22 |
ASX - By Stock
|
129
|
59K
|
15
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm on the television .
|
|
5cata
|
63 |
26K |
1 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
63
|
26K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Appoints Experienced US-Based CEO
|
|
5cata
|
82 |
32K |
0 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
82
|
32K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Worse Case
|
|
5cata
|
54 |
26K |
0 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
54
|
26K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Phase 3 trial
|
|
5cata
|
5 |
2.8K |
1 |
26/02/22 |
26/02/22 |
ASX - By Stock
|
5
|
2.8K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
PAR Investor Meeting - Questions from HC
|
|
5cata
|
122 |
39K |
5 |
20/12/21 |
20/12/21 |
ASX - By Stock
|
122
|
39K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
|
|
5cata
|
45 |
16K |
0 |
19/12/21 |
19/12/21 |
ASX - By Stock
|
45
|
16K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
5cata
|
408 |
124K |
1 |
18/12/21 |
18/12/21 |
ASX - By Stock
|
408
|
124K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Novartis Agreement
|
|
5cata
|
850 |
252K |
2 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
850
|
252K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
OTAT Meeting
|
|
5cata
|
36 |
9.5K |
3 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
36
|
9.5K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Novartis Agreement
|
|
5cata
|
850 |
252K |
10 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
850
|
252K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
5cata
|
4.1K |
1.9M |
1 |
27/11/21 |
27/11/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
5cata
|
4.1K |
1.9M |
2 |
27/11/21 |
27/11/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Norvatis Anniversary
|
|
5cata
|
58 |
14K |
2 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
58
|
14K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
5cata
|
4.1K |
1.9M |
0 |
04/07/21 |
04/07/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - Day Trading
|
|
Re:
Day traders' after-market lounge May 4
|
|
5cata
|
61 |
12K |
0 |
04/05/21 |
04/05/21 |
ASX - Day Trading
|
61
|
12K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
5cata
|
1.6K |
465K |
4 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
1.6K
|
465K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
5cata
|
1.6K |
465K |
21 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
1.6K
|
465K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
5cata
|
17K |
6.7M |
6 |
01/05/21 |
01/05/21 |
ASX - By Stock
|
17K
|
6.7M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Consistent pain reduction and improvement in function data
|
|
5cata
|
106 |
30K |
0 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
106
|
30K
|
0
|
|
ASX - By Stock
|
MYL |
Re:
Ann: Interview - MYL to Acquire Wuntho Project
|
|
5cata
|
29 |
10K |
15 |
25/01/21 |
25/01/21 |
ASX - By Stock
|
29
|
10K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
CHF - The real phase 3 headlines
|
|
5cata
|
147 |
73K |
1 |
29/12/20 |
29/12/20 |
ASX - By Stock
|
147
|
73K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
CHF - The real phase 3 headlines
|
|
5cata
|
147 |
73K |
1 |
29/12/20 |
29/12/20 |
ASX - By Stock
|
147
|
73K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: R&D Investor Presentation
|
|
5cata
|
91 |
35K |
0 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
91
|
35K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
3 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
2 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Irrational gloom
|
|
5cata
|
64 |
28K |
2 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
64
|
28K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
3 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Novartis deal on the rocks
|
|
5cata
|
247 |
89K |
3 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
247
|
89K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
3 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
0 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
5cata
|
183 |
94K |
2 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
94K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
2 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
0 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
11 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
5cata
|
1.0K |
517K |
8 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
pick the price of a take over bid
|
|
5cata
|
31 |
12K |
2 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
31
|
12K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
5cata
|
796 |
395K |
0 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
796
|
395K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Guess the reason for MSB Trading Halt
|
|
5cata
|
317 |
157K |
1 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
317
|
157K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Guess the reason for MSB Trading Halt
|
|
5cata
|
317 |
157K |
7 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
317
|
157K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
5cata
|
796 |
395K |
2 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
395K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
5cata
|
796 |
395K |
0 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
395K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
5cata
|
796 |
395K |
5 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
395K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
5cata
|
344 |
180K |
7 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
344
|
180K
|
7
|
|